Omeprazole induces gastric permeability to digoxin

Digestive Diseases and Sciences

Volumn 55, Issue 5, 2010, Pages 1255-1263

  Gabello, M ^a,b   Valenzano, M C ^a   Barr, M ^c   Zurbach, P ^b   Mullin, J M ^a,c  

^a Medical Research   (United States)

^b SAINT JOSEPH S UNIVERSITY   (United States)

^c LANKENAU HOSPITAL   (United States)

Author keywords

Digoxin; Omeprazole; Paracellular; Proton pump inhibitor; Tight junction; Transepithelial

Indexed keywords

CYTOCHROME P450; DIGOXIN; OMEPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIGOXIN BLOOD LEVEL; DRUG PENETRATION; DRUG POTENTIATION; DRUG UPTAKE; MALE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; RAT; STOMACH MUCOSA; THIN LAYER CHROMATOGRAPHY; TIGHT JUNCTION; ANIMAL; DRUG EFFECT; ELECTROPHYSIOLOGY; IN VITRO STUDY; PERMEABILITY; PH; SPRAGUE DAWLEY RAT;

ANIMALS; CHROMATOGRAPHY, THIN LAYER; DIGOXIN; ELECTROPHYSIOLOGY; GASTRIC MUCOSA; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; PERMEABILITY; PHENYTOIN; PROTON PUMP INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TIGHT JUNCTIONS;

EID: 77953626475     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0851-z     Document Type: Article

References (25)

1. Mullin JM, Valenzano MC, Whitby M et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability (R2). Aliment Pharmacol Ther. 2008.
2. Murray LJ, Gabello M, Rudolph DS et al. Transmucosal gastric leak induced by proton pump inhibitors. Dig Dis Sci. 2009.
3. Hopkins AM, McDonnell C, Breslin NP, O'Morain CA, Baird AW. Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue. J Pharm Pharmacol. 2002;54:341-347. doi:10.1211/ 0022357021778583. (Pubitemid 34232335)
4. Mulrow CD, Feussner JR, Velez R. Reevaluation of digitalis efficacy. New light on an old leaf. Ann Intern Med. 1984;101:113-117.
5. Appleton R, Macleod S, Martland T. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2008;3:CD001905.
6. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944. doi:10.1001/jama.2009.261.
7. Peterson KU. Review article: Omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther. 1995;9:1-9.
8. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63:2739-2754. doi:10.2165/00003495-200363240-00004. (Pubitemid 38049991)
9. Dobson JG Jr, Kidder GW. Edge damage effect in vitro frog skin preparations. Am J Physiol. 1968;214:719-724.
10. Walser M. Role of edge damage in sodium permeability of toad bladder and ameans of avoiding it. Am J Physiol. 1970;219:252-255.
11. Svelto M, Perrini MCR, Lippe C. Properties of the frog skin at various degrees of edge damage. Arch Int Physiol Biochim. 1975;83:837-843. doi:10.3109/13813457509069514.
12. Kleinzeller A, McAvoy EM, McKibbin RD. Active renal hexose transport. Structural requirements. Biochim Biophys Acta. 1980;600:513-529. doi:10.1016/0005-2736(80)90453-8.
13. Humphries TJ, Merritt GJ. Drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther. 1999;13(Suppl 3):18-26. doi:10.1046/j.1365-2036.1999.00021.x. (Review article).
14. Andersson T, Lagerström PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit. 1990;12:329-333.
15. Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. Br J Clin Pharmacol. 1993;36:380-382.
16. Middle MV, Müller FO, Schall R, et al. No influence of pantoprazole on the pharmacokinetics of phenytoin. Clin Pharmacol Ther. 1996;34:S72-S75.
17. Karol MD, Locke CS, Cavanaugh JH. Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin. J Clin Pharmacol. 1999;39:1283-1289. doi:10.1177/00912709922011971.
18. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet. 1991;20:38-49. doi:10.2165/00003088-199120010-00003.
19. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet. 1991;21:195-212. doi:10.2165/00003088-199121030-00004.
20. Cederberg C, Andersson T, Skånberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol. 1989;166:33-42. doi:10.3109/00365528909091241.
21. Robertson DS. The chemical reactions in the human stomach and the relationship to metabolic disorders. Med Hypotheses. 2005;64:1127-1131. doi:10.1016/j.mehy.2004.12.018.
22. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871-878. doi:10.1001/jama.289.7.871. (Pubitemid 37430346)
23. Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther. 1994;32:385-399.
24. Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32:569-572.
25. Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J. 2007;100:400-402.